MACK Stock Price, Merrimack Pharmaceuticals Quote, Chart

Market Summary

USD15.16+0.03

Delayed

0.20%

MACK Stock Price

View Fullscreen

MACK RSI Chart

MACK Valuation

Market Cap

224.2M

Price/Earnings (Trailing)

1.12

Price/Sales (Trailing)

45.57

EV/EBITDA

8.53

Price/Free Cashflow

-166.31

MACK Price/Sales (Trailing)

MACK Profitability

Operating Margin

-40.77%

EBT Margin

-23.81%

Return on Equity

90.44%

Return on Assets

82.05%

Free Cashflow Yield

-0.6%

MACK Fundamentals

MACK Revenue

Revenue (TTM)

4.9M

MACK Earnings

Earnings (TTM)

200.5M

Earnings Growth (Yr)

74.4K%

Earnings Growth (Qtr)

84.0K%

Breaking Down MACK Revenue

Last 7 days

0.3%

Last 30 days

3.3%

Last 90 days

3.1%

Trailing 12 Months

18.7%

How does MACK drawdown profile look like?

MACK Financial Health

Current Ratio

10.78

Debt/Equity

0.23

Debt/Cashflow

-0.03

MACK Investor Care

Dividend Yield

13.22%

Dividend/Share (TTM)

2

Shares Dilution (1Y)

3.70%

Diluted EPS (TTM)

13.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	0	2.8M	3.8M	4.9M
2017	0	96.7M	49.2M	1.7M
2016	95.7M	92.8M	104.5M	144.3M
2015	104.6M	113.3M	101.7M	89.3M
2014	46.2M	55.5M	76.7M	102.8M
2013	52.2M	58.6M	54.2M	47.8M
2012	39.1M	44.6M	47.3M	48.9M
2011	23.8M	27.3M	30.7M	34.2M
2010	0	0	0	20.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Merrimack Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 28, 2023	andersen eric	bought	11,441	13.3503	857	-
Dec 26, 2023	andersen eric	bought	640,313	13.15	48,693	-
Dec 07, 2023	andersen eric	bought	1,298,470	12.8498	101,050	-
Nov 17, 2023	andersen eric	bought	3,750	12.5	300	-
Nov 14, 2023	andersen eric	bought	627,125	12.5	50,170	-
Nov 13, 2023	andersen eric	bought	192,875	12.3876	15,570	-
Nov 10, 2023	andersen eric	bought	469,008	12.3222	38,062	-
Nov 09, 2023	andersen eric	bought	121,618	12.1923	9,975	-
Nov 08, 2023	andersen eric	bought	167,701	12.132	13,823	-
Aug 11, 2023	crocker gary l	bought	24,865	12.4326	2,000	see remarks

Which funds bought or sold MACK recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	680	7,385	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	164,301	164,301	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.89	-7,552	15,553	-%
May 15, 2024	Madison Avenue Partners, LP	reduced	-29.99	-1,697,620	5,719,250	0.92%
May 15, 2024	Western Standard LLC	unchanged	-	2,954,620	32,088,000	15.37%
May 15, 2024	Indaba Capital Management, L.P.	sold off	-100	-2,996,580	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-77.88	-12,841	4,136	-%
May 15, 2024	Newtyn Management, LLC	unchanged	-	2,548,220	27,674,500	5.51%
May 15, 2024	Aristides Capital LLC	new	-	147,700	147,700	0.05%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	159,516	159,516	-%

Are Funds Buying or Selling MACK?

Are funds buying MACK calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MACK

No. of Funds

Unveiling Merrimack Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 07, 2024	blackrock inc.	4.99%	715,279	SC 13G/A
Feb 14, 2024	22nw fund, lp	-	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.2%	743,623	SC 13G
Jan 25, 2024	newtyn management, llc	13.1%	1,873,694	SC 13D/A
Dec 13, 2023	western standard llc	15.5%	2,220,058	SC 13D/A
Aug 14, 2023	western standard llc	13.9%	1,991,108	SC 13D/A
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 13, 2023	22nw fund, lp	7.6%	1,015,048	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	4.3%	569,971	SC 13G/A
Feb 14, 2022	22nw, lp	9.3%	1,241,896	SC 13G/A

Recent SEC filings of Merrimack Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 10, 2024	25	25
May 10, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
May 09, 2024	DEFA14A	DEFA14A
Apr 30, 2024	8-K	Current Report
Apr 30, 2024	DEFA14A	DEFA14A
Apr 01, 2024	DEFR14A	DEFR14A
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	DEFA14A	DEFA14A

Peers (Alternatives to Merrimack Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Merrimack Pharmaceuticals Inc News

Latest updates

Merrimack Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2017Q4	2017Q3	2017Q2	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2
Revenue	-	-	-	1.00	-	20.00	41.00	61.00	28.00	34.00	21.00	21.00	16.00	37.00	15.00	34.00	28.00	28.00	13.00	8.00	7.00	18.00
Cost Of Revenue	-	-	-	-	-	-	-	3.00	1.00	2.00	1.00	0.00	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	17.00	17.00	35.00	42.00	36.00	36.00	34.00	-9.63	55.00	55.00	45.00	39.00	52.00	42.00	37.00	36.00	43.00	48.00
Operating Expenses	161.3%	2.00	1.00	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-49.1%	2.00	4.00	6.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-	-	-	5.00	12.00	14.00	20.00	26.00	28.00	28.00	28.00	38.00	30.00	26.00	26.00	31.00	44.00	34.00	30.00	-	-	-
Interest Expenses	-	0.00	-	1.00	4.00	2.00	27.00	2.00	2.00	16.00	3.00	5.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	4.00	-	-
Income Taxes	-	-	-	-	-10.03	-2.13	-30.24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-2.15	-	-	-21.86	-7.46	-59.88	-43.54	-36.61	-51.63	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	562.6%	3.00	-0.70	-9.43	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1173.3%	244	19.00	19.00	19.00	20.00	20.00	14.00	14.00	15.00	15.00	15.00	16.00	16.00	17.00	19.00	20.00	21.00	20.00	25.00	45.00	74.00
Current Assets	1173.6%	244	19.00	19.00	19.00	20.00	20.00	14.00	14.00	15.00	15.00	15.00	16.00	16.00	17.00	19.00	19.00	20.00	19.00	22.00	43.00	64.00
Cash Equivalents	3809.8%	234	6.00	6.00	10.00	19.00	19.00	13.00	13.00	14.00	14.00	15.00	15.00	14.00	14.00	16.00	16.00	18.00	17.00	21.00	37.00	37.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00
Liabilities	95.7%	23.00	12.00	0.00	0.00	0.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	3.00	3.00	5.00	5.00	25.00
Current Liabilities	5041.0%	23.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	3.00	3.00	5.00	5.00	12.00
Shareholder's Equity	1082.3%	222	19.00	19.00	19.00	19.00	19.00	13.00	14.00	14.00	14.00	15.00	15.00	16.00	16.00	17.00	17.00	18.00	17.00	20.00	40.00	49.00
Retained Earnings	36.7%	-347	-548	-548	-548	-547	-547	-547	-546	-546	-546	-545	-545	-544	-543	-542	-541	-540	-540	-543	-543	-533
Additional Paid-In Capital	0.3%	568	566	566	566	566	566	559	559	559	559	559	559	559	558	558	558	557	557	563	582	581
Shares Outstanding	1.3%	15.00	14.00	14.00	14.00	14.00	14.00	13.00	13.00	13.00	13.00	13.00	13.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	130	-	-	-	130	-	-	-	68.00	-	-	-	44.00	-	-	-	79.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	29.8%	-226	-322	-176	-624	-400	-185	-264	-939	-354	-355	-445	1,019	-437	-1,776	135	-1,979	-1,005	-2,640	-3,203	-11,873	-13,652
Cashflow From Investing	335194.1%	228,000	68.00	-3,845	-8,811	139	-	-	-	445	-	94.00	-	50.00	-	-	-311	2,450	5,000	6,500	28,210	30,115
Cashflow From Financing	1016.5%	1,485	133	-	209	179	-	-	-	-	-	-	-	239	-	-	-	-	-6,638	-19,940	-	-
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,700	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MACK Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
General and administrative expenses	$ 669	$ 586
Gain on sale of in-process research and development		(139)
Total operating expenses	669	447
Loss from operations	(669)	(447)
Other income:
Interest income	233	176
Total other income	233	176
Net loss from continuing operations	(436)	(271)
Discontinued operations:
Income from discontinued operations, net of tax	201,806
Net income and comprehensive income	$ 201,370	$ (271)
Basic and dilutive net income (loss) per common share
Net loss from continuing operations - basic	$ (0.03)	$ (0.02)
Net loss from continuing operations - diluted	(0.03)	(0.02)
Net income from discontinued operations, net of tax - basic	13.96
Net income from discontinued operations, net of tax - diluted	13.96
Net income (loss) per common share - basic	13.93	(0.02)
Net income (loss) per common share - diluted	$ 13.93	$ (0.02)
Weighted-average common shares used to compute basic net income (loss) per common share	14,452	14,252
Weighted-average common shares used to compute diluted net income (loss) per common share	14,452	14,252

MACK Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 234,160	$ 5,989
Short-term investments	9,950	12,886
Prepaid expenses and other current assets	209	309
Total current assets	244,319	19,184
Other assets	3	4
Total assets	244,322	19,188
Current liabilities:
Accounts payable, accrued expenses and other	566	441
Income taxes payable	22,106
Total current liabilities	22,672	441
Total liabilities	22,672	441
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value: 10,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 or December 31, 2023
Common stock, $0.01 par value: 30,000 shares authorized at March 31, 2024 and December 31, 2023; 14,532 and 14,351 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	1,345	1,343
Additional paid-in capital	567,752	566,221
Accumulated deficit	(347,447)	(548,817)
Total stockholders’ equity	221,650	18,747
Total liabilities and stockholders’ equity	$ 244,322	$ 19,188

About Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

0

CEO	Mr. Gary L. Crocker M.B.A., MBA
WEBSITE	merrimack.com
INDUSTRY	Biotechnology

Merrimack Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Merrimack Pharmaceuticals Inc? What does MACK stand for in stocks?

MACK is the stock ticker symbol of Merrimack Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merrimack Pharmaceuticals Inc (MACK)?

As of Fri May 17 2024, market cap of Merrimack Pharmaceuticals Inc is 224.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MACK stock?

You can check MACK's fair value in chart for subscribers.

What is the fair value of MACK stock?

You can check MACK's fair value in chart for subscribers. The fair value of Merrimack Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merrimack Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MACK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merrimack Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MACK is over valued or under valued. Whether Merrimack Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Merrimack Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MACK.

What is Merrimack Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MACK's PE ratio (Price to Earnings) is 1.12 and Price to Sales (PS) ratio is 45.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MACK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merrimack Pharmaceuticals Inc's stock?

In the past 10 years, Merrimack Pharmaceuticals Inc has provided -0.071 (multiply by 100 for percentage) rate of return.